Skip to main content
. 2023 Jan 5;15(2):352. doi: 10.3390/cancers15020352

Figure 2.

Figure 2

Post-HCT outcomes for 583 adults with AML undergoing allogeneic HCT following myeloablative conditioning while in first or second morphologic remission, stratified by disease status at diagnosis (de novo vs. therapy-related vs. antecedent hematologic disorder): (A) Non-relapse mortality; (B) relapse; (C) relapse-free survival; and (D) overall survival.